BRPI1009448A2 - combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos - Google Patents

combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos

Info

Publication number
BRPI1009448A2
BRPI1009448A2 BRPI1009448A BRPI1009448A BRPI1009448A2 BR PI1009448 A2 BRPI1009448 A2 BR PI1009448A2 BR PI1009448 A BRPI1009448 A BR PI1009448A BR PI1009448 A BRPI1009448 A BR PI1009448A BR PI1009448 A2 BRPI1009448 A2 BR PI1009448A2
Authority
BR
Brazil
Prior art keywords
edea119
bay
treatment
pharmaceutical combinations
specific cancers
Prior art date
Application number
BRPI1009448A
Other languages
English (en)
Inventor
Mark S Chapman
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42135921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1009448(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of BRPI1009448A2 publication Critical patent/BRPI1009448A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI1009448A 2009-03-11 2010-03-11 combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos BRPI1009448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15940309P 2009-03-11 2009-03-11
PCT/US2010/027060 WO2010105110A1 (en) 2009-03-11 2010-03-11 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers

Publications (1)

Publication Number Publication Date
BRPI1009448A2 true BRPI1009448A2 (pt) 2016-03-01

Family

ID=42135921

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009448A BRPI1009448A2 (pt) 2009-03-11 2010-03-11 combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos

Country Status (23)

Country Link
US (2) US8673876B2 (pt)
EP (1) EP2405908B1 (pt)
JP (2) JP5767122B2 (pt)
KR (1) KR20110132371A (pt)
CN (2) CN102421427B (pt)
AU (1) AU2010224044A1 (pt)
BR (1) BRPI1009448A2 (pt)
CA (2) CA2754913C (pt)
CL (1) CL2011002233A1 (pt)
CO (1) CO6430423A2 (pt)
CR (1) CR20110479A (pt)
CU (1) CU20110170A7 (pt)
DO (1) DOP2011000282A (pt)
EA (1) EA201101302A1 (pt)
EC (1) ECSP11011314A (pt)
HK (2) HK1169603A1 (pt)
IL (1) IL214749A0 (pt)
MA (1) MA33091B1 (pt)
MX (1) MX2011009498A (pt)
PE (1) PE20120105A1 (pt)
SG (1) SG174272A1 (pt)
TN (1) TN2011000455A1 (pt)
WO (1) WO2010105110A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2013001372A2 (en) * 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
WO2014071183A1 (en) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2848246A1 (en) * 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
WO2002039958A2 (en) * 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2002340139A1 (en) * 2001-10-09 2003-04-22 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
EP1620109A2 (en) * 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2006066267A2 (en) * 2004-12-17 2006-06-22 Smithkline Beecham (Cork) Limited Cancer treatment method
US20060211074A1 (en) * 2005-01-12 2006-09-21 Boyce James P Kinase-directed, activity-based probes
EP1859797A4 (en) * 2005-02-28 2011-04-13 Eisai R&D Man Co Ltd NEW SIMULTANEOUS USE OF A SULPHONAMIDE COMPOUND AND A MEDIUM AGAINST CANCER
US8648116B2 (en) * 2005-07-21 2014-02-11 Ardea Biosciences, Inc. Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
US20100291593A1 (en) * 2007-07-13 2010-11-18 Powell William C Method of identifying diagnostic reagents
CA2693390C (en) * 2007-07-30 2017-01-17 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
DE102008031039A1 (de) * 2008-06-30 2009-12-31 Dömling, Alexander, Priv.-Doz. Dr. Tarceva zur Anwendung in der Organtransplantation.

Also Published As

Publication number Publication date
CL2011002233A1 (es) 2012-02-03
ECSP11011314A (es) 2011-10-31
JP5767122B2 (ja) 2015-08-19
SG174272A1 (en) 2011-10-28
MX2011009498A (es) 2011-10-14
CU20110170A7 (es) 2012-06-21
WO2010105110A1 (en) 2010-09-16
PE20120105A1 (es) 2012-02-22
CN103948600A (zh) 2014-07-30
US20140080783A1 (en) 2014-03-20
EA201101302A1 (ru) 2012-05-30
MA33091B1 (fr) 2012-03-01
US8673876B2 (en) 2014-03-18
TN2011000455A1 (en) 2013-03-27
AU2010224044A1 (en) 2011-09-22
CR20110479A (es) 2011-10-24
CO6430423A2 (es) 2012-04-30
IL214749A0 (en) 2011-11-30
CA2754913A1 (en) 2010-09-16
DOP2011000282A (es) 2011-10-15
US20120071435A1 (en) 2012-03-22
EP2405908A1 (en) 2012-01-18
JP2012520321A (ja) 2012-09-06
KR20110132371A (ko) 2011-12-07
CN102421427A (zh) 2012-04-18
JP5911929B2 (ja) 2016-04-27
HK1169603A1 (en) 2013-02-01
CA2754913C (en) 2017-08-22
US9220696B2 (en) 2015-12-29
CA2972379A1 (en) 2010-09-16
EP2405908B1 (en) 2016-12-21
HK1199710A1 (en) 2015-07-17
JP2014237716A (ja) 2014-12-18
CN102421427B (zh) 2013-11-06

Similar Documents

Publication Publication Date Title
IL255752B (en) Compounds, pharmaceutical preparations containing the same uses for the treatment of cardiovascular disease, inflammatory diseases and cancer
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BR112013010157A2 (pt) inibidores do ibat para o tratamento de doenças do fígado
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
IL218971A0 (en) Sulfoxide derivatives for the treatment of tumours
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0922884A2 (pt) compostos para tratamento de câncer
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]